Note: Schedules filed in paper format shall include
a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7(b) for other parties to whom
copies are to be sent.
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of
this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act
of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
SCHEDULE 13D
CUSIP
No. 44919F 104 |
|
Page 2
of 6 Pages |
1 |
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Acuitas Group Holdings, LLC |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
(b) ¨ |
3 |
SEC
USE ONLY |
4 |
SOURCE OF FUNDS (See Instructions)
OO |
5 |
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) |
¨ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
California |
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
7 |
SOLE VOTING POWER
0 |
8 |
SHARED VOTING POWER
11,155,575 |
9 |
SOLE DISPOSITIVE POWER
0 |
10 |
SHARED DISPOSITIVE POWER
11,155,575 |
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11,155,575 |
12 |
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) |
¨ |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
41.3%1 |
14 |
TYPE OF REPORTING PERSON (See Instructions)
OO |
|
|
|
|
|
|
|
1 |
Based on 27,034,375 Shares
issued and outstanding as of November 15, 2022, as disclosed in the Quarterly Report on Form 10-Q filed by the Company
with the SEC on November 21, 2022 (the “Form 10-Q”). |
SCHEDULE 13D
CUSIP
No. 44919F 104 |
|
Page 3
of 6 Pages |
1 |
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Terren S. Peizer |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
(b) ¨ |
3 |
SEC
USE ONLY |
4 |
SOURCE OF FUNDS (See Instructions)
OO |
5 |
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) |
¨ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
7 |
SOLE VOTING POWER
11,155,575 |
8 |
SHARED VOTING POWER
0 |
9 |
SOLE DISPOSITIVE POWER
11,155,575 |
10 |
SHARED DISPOSITIVE POWER
0 |
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11,155,575 |
12 |
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) |
¨ |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
41.3%2 |
14 |
TYPE OF REPORTING PERSON (See Instructions)
HC; IN |
|
|
|
|
|
|
|
2 |
Based on 27,034,375 Shares
issued and outstanding as of November 15, 2022, as disclosed in the Form 10-Q. |
CUSIP
No. 44919F 104 |
|
Page 4
of 6 Pages |
AMENDMENT NO. 13 TO SCHEDULE 13D
This Amendment No. 13
to Schedule 13D (this “Amendment”) is being filed by Acuitas Group Holdings, LLC, a California limited liability company
(“Acuitas”), and Terren S. Peizer (“Mr. Peizer”) (collectively, the “Reporting Persons”)
to amend the Schedule 13D originally filed with the Securities and Exchange Commission (the “SEC”) on October 20,
2010, as amended by Amendment No. 1 to Schedule 13D filed on December 6, 2011, Amendment No. 2 to Schedule 13D filed on
April 27, 2012, Amendment No. 3 to Schedule 13D filed on September 20, 2012, Amendment No. 4 to Schedule 13D filed
on February 14, 2013, Amendment No. 5 to Schedule 13D filed on May 11, 2021, Amendment No. 6 to Schedule 13D filed
on July 27, 2021, Amendment No. 7 to Schedule 13D filed on August 16, 2021, Amendment No. 8 to Schedule 13D filed
on November 2, 2021, Amendment No. 9 to Schedule 13D filed on April 18, 2022, Amendment No. 10 to Schedule 13D filed
on September 2, 2022, Amendment No. 11 to Schedule 13D filed on September 8, 2022 and Amendment No. 12 to Schedule
13D filed on November 22, 2022 (as amended and supplemented, the “Original Statement” and, as amended and supplemented
by this Amendment, the “Statement”), relating to common stock, par value $0.0001 per share (the “Shares”),
of OnTrak, Inc., a Delaware corporation (the “Company”). Capitalized terms used herein but not defined have the
respective meanings ascribed to them in the Original Statement.
|
ITEM
4. |
PURPOSE
OF TRANSACTION |
Item 4 of the Statement is
hereby amended and supplemented by adding the following information:
“As previously disclosed,
on April 15, 2022, Acuitas Capital LLC (“Acuitas Capital”), an entity wholly owned by Acuitas, and the Company
entered into a Master Note Purchase Agreement, as amended by that certain First Amendment thereto, dated as of August 12, 2022,
and that certain Second Amendment thereto, dated as of November 19, 2022 (as amended to date, the “Keep Well Agreement”),
pursuant to which, subject to specified conditions, the Company may borrow up to $25.0 million from time to time. In connection with
each borrowing under the Keep Well Agreement, the Company agreed to issue a senior secured note to Acuitas Capital or an entity affiliated
with it for the amount borrowed (each such note, a “Keep Well Note”). In addition, in connection with each Keep Well
Note sold by the Company, the Company agreed to issue Acuitas Capital (or an affiliated entity designated by Acuitas Capital) warrants
to purchase up to 2,958,580 Shares, in the form attached as an exhibit to the Keep Well Agreement (the “Keep Well Warrants”),
all upon the terms and subject to the conditions specified in the Keep Well Agreement.
As previously disclosed,
pursuant to the Keep Well Agreement, the Company issued and sold to Acuitas Capital Keep Well Notes in the principal amounts of $5,000,000
and $6,000,000 on July 15, 2022 and September 7, 2022, respectively. In connection with the issuance and sale of such notes,
the Company issued to Acuitas Keep Well Warrants to purchase 591,716 Shares and 710,059 Shares on August 29, 2022 and September 7,
2022, respectively (without giving effect to the increase in the warrant coverage contemplated by the Second Amendment to the Keep Well
Agreement, as previously described in this Item 4).
On December 30, 2022,
the Company and Acuitas Capital entered into an amendment (the “Third Amendment”) to the Keep Well Agreement pursuant
to which, as further described below, the Company and Acuitas Capital agreed that (a) the minimum conversion price of the Keep Well
Notes and (b) the minimum dollar amount to which the denominator will be reduced for purposes of calculating the warrant coverage
on future borrowings under the Keep Well Agreement, will be $0.15 (subject to adjustment for stock splits or other recapitalizations
that affect all common stockholders proportionately).
As previously disclosed,
pursuant to the Keep Well Agreement, subject to stockholder approval, (1) Acuitas Capital, at its option, will have the right to
convert the entire outstanding principal amount of the Keep Well Notes, plus all accrued and unpaid interest thereon, in whole or in
part, into Shares at a conversion price equal to the lesser of (a) $0.40 per share and (b) the closing price of the Company’s
common stock on the trading day immediately prior to the applicable conversion date, and (2) in connection with any such conversion,
the Company will issue to Acuitas Capital a five-year warrant to purchase such number of Shares equal to (x) 100% of the amount
converted divided by (y) the conversion price then in effect. As a result of the Third Amendment, under no circumstances will the
conversion price described in clause (1) of the preceding sentence (including for purposes of calculating the warrant coverage on
the conversion of any amount outstanding under any Keep Well Note into Shares, as described in clause (2) of the preceding sentence)
be less than $0.15 (subject to adjustment for stock splits or other recapitalizations that affect all common stockholders proportionately,
as described above).
Also as previously disclosed,
pursuant to the Keep Well Agreement, subject to stockholder approval, the warrant coverage on future borrowings under the Keep Well Agreement
will be equal to (a) 100% of the amount borrowed under the Keep Well Agreement divided by (b) $0.45, subject to future adjustment
based on, among other future events, the closing price of the Company’s common stock on the trading day immediately preceding the
final funding date under the Keep Well Agreement. As a result of the Third Amendment, under no circumstances will the dollar amount of
the denominator for calculating the warrant coverage on future borrowings under the Keep Well Agreement described in clause (b) of
the preceding sentence be less than $0.15 (subject to adjustment for stock splits or other recapitalizations that affect all common stockholders
proportionately, as described above).
CUSIP
No. 44919F 104 |
|
Page 5
of 6 Pages |
Also as previously disclosed,
(a) under no circumstances will the Company issue any shares upon exercise of any warrant issued under the Keep Well Agreement or
upon conversion of any Keep Well Note to the extent that, after giving effect to the issuance of any such shares, Acuitas Capital (together
with its affiliates) would beneficially own Shares representing more than 90% of the total number of Shares outstanding as of the time
of such issuance (the “Issuance Cap”), and (b) in the event of a Fundamental Transaction (as defined in the Keep
Well Agreement), regardless of the actual number of securities of the Company beneficially owned by Acuitas Capital and its affiliates
at the effective time thereof, Acuitas Capital shall not be entitled to receive any consideration pursuant to such Fundamental Transaction
in respect of any shares underlying any of the warrants issued under the Keep Well Agreement or any shares issuable upon conversion of
any Keep Well Note that would represent shares in excess of the Issuance Cap if beneficially owned by Acuitas Capital and/or its affiliates
immediately prior to such effective time, and all warrants and Keep Well Notes owned or beneficially owned by Acuitas Capital and/or
its affiliates at the effective time of such Fundamental Transaction, solely to the extent that, if exercised or converted, such warrants
and Keep Well Notes would result in the issuance of such excess shares, will be cancelled and forfeited without consideration therefor,
effective as of such effective time; provided, however, that the foregoing shall not affect the Company’s obligation to pay all
amounts owed under such Keep Well Notes in connection with such Fundamental Transaction.
The foregoing descriptions
of the Third Amendment, the Keep Well Note and the Keep Well Warrant are qualified in their entirety by reference to the full text of
the Third Amendment, the amended form of the Keep Well Note and the amended form of the Keep Well Warrant, which are attached hereto
as Exhibits 99.18, 99.19 and 99.20, respectively, and incorporated by reference herein.”
|
ITEM 6. |
Contracts,
arrangements, understandings or relationships with respect to the securities of the issuer |
Item 6 of the Statement is
hereby amended and supplemented to include the information disclosed in Item 4 above, which information is incorporated by reference
herein.
|
ITEM
7. |
MATERIALS
TO BE FILED AS EXHIBITS |
Item 7 of the Statement is
hereby amended and supplemented by adding the following:
CUSIP
No. 44919F 104 |
|
Page 6
of 6 Pages |
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: January 4, 2023
|
ACUITAS GROUP HOLDINGS, LLC |
|
|
|
By: |
/s/
Terren S. Peizer |
|
|
Terren S. Peizer, Chairman |
|
|
|
/s/
Terren S. Peizer |
|
Terren S. Peizer |